Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	27,796	17,139	4,757	7,884	8,458	9,860
Short-Term Investments	68,588	75,923	74,450	56,515	37,671	18,675
Trading Asset Securities	-	-	8,247	5,933	19,239	29,299
Cash & Short-Term Investments	96,384	93,062	87,454	70,332	65,368	57,834
Cash Growth	11.95%	6.41%	24.34%	7.59%	13.03%	5.37%
Accounts Receivable	4,169	4,357	3,991	4,595	4,566	4,664
Other Receivables	2,450	736.95	682.88	943.86	583.11	268.43
Receivables	6,810	5,362	4,976	5,740	5,330	5,216
Inventory	5,409	4,616	4,203	4,122	4,102	3,589
Prepaid Expenses	900.92	459.01	287.27	691.85	500.5	292.5
Other Current Assets	253.98	214.29	228.19	1,044	354.58	587.81
Total Current Assets	109,757	103,712	97,148	81,929	75,655	67,519
Property, Plant & Equipment	32,831	30,460	30,463	32,937	33,638	34,057
Long-Term Investments	501.94	501.94	501.94	501.94	3,786	8,427
Other Intangible Assets	1,155	1,176	1,606	1,599	1,793	1,536
Long-Term Accounts Receivable	0	0	0	0	0	0
Long-Term Deferred Tax Assets	270.14	270.14	216.96	182.29	449.3	751.56
Other Long-Term Assets	411.68	452.94	461.66	491.37	517.21	585.15
Total Assets	144,926	136,572	130,398	117,641	115,839	112,877

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	964.86	458.36	680.27	578.39	1,370	1,224
Accrued Expenses	947.77	395.45	481.51	489.15	443.91	470.95
Current Portion of Leases	84.54	350.13	650.28	621.14	600.78	402.89
Current Income Taxes Payable	1,771	187.23	1,404	-	1,038	814.73
Current Unearned Revenue	30.52	33.27	27.57	27.03	30.9	50.44
Other Current Liabilities	4,311	3,436	2,619	3,106	3,905	2,802
Total Current Liabilities	8,110	4,861	5,863	4,821	7,389	5,766
Long-Term Leases	74.31	75.25	366.66	934.17	357.79	423.49
Other Long-Term Liabilities	-	0	-	-	-	0
Total Liabilities	8,184	4,936	6,229	5,755	7,747	6,189

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	4,260	12,760	12,760	12,760	12,760	12,760
Retained Earnings	150,661	137,309	130,264	118,217	114,993	109,894
Treasury Stock	-23,978	-23,978	-23,978	-23,978	-23,978	-20,258
Comprehensive Income & Other	1,100	845.33	422.69	186.4	-382.91	-408.42
Shareholders' Equity	136,743	131,637	124,168	111,885	108,092	106,687
Total Liabilities & Equity	144,926	136,572	130,398	117,641	115,839	112,877

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	158.86	425.38	1,017	1,555	958.57	826.38
Net Cash (Debt)	96,225	92,636	86,437	68,777	64,409	57,007
Net Cash Growth	12.72%	7.17%	25.68%	6.78%	12.98%	6.47%
Net Cash Per Share	14052.47	13535.60	12628.32	10049.37	9342.06	8061.43
Filing Date Shares Outstanding	6.84	6.84	6.84	6.84	6.84	7.07
Total Common Shares Outstanding	6.84	6.84	6.84	6.84	6.84	7.07
Working Capital	101,648	98,852	91,286	77,108	68,266	61,754
Book Value Per Share	19983.77	19234.14	18142.94	16348.17	15793.91	15086.68
Tangible Book Value	135,588	130,461	122,563	110,286	106,299	105,151
Tangible Book Value Per Share	19814.96	19062.36	17908.31	16114.53	15531.88	14869.49
Land	9,696	9,696	9,696	9,765	9,765	9,765
Buildings	25,310	22,296	19,675	19,537	13,349	13,854
Machinery	26,552	26,322	25,847	25,644	7,228	8,033
Construction In Progress	751.01	117.7	385.42	338.95	993.9	247.26